Subgroup (B); non-SC EP-NECs with a Ki-67 index of ≥55% yielded the worst prognosis within the whole EP-NEC family; a possible explanation for the poor outcomes of this subgroup is its reduced platinum-sensitivity and alternative non-platinum/etoposide-based chemotherapy regimens or different treatment strategies, especially inclusion in clinical trials, should be considered for this subgroup. The gene discussed is MKI67; the disease is neuroendocrine carcinoma.